These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 6119205)

  • 41. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sulphasalazine in inflammatory bowel disease: recent advances.
    Cooper BT
    N Z Med J; 1986 Oct; 99(811):757-9. PubMed ID: 2877428
    [No Abstract]   [Full Text] [Related]  

  • 43. [Drug treatment of chronic inflammatory diseases of the intestine].
    Modigliani R
    Schweiz Med Wochenschr; 1988 May; 118(20):737. PubMed ID: 2898809
    [No Abstract]   [Full Text] [Related]  

  • 44. The treatment of inflammatory bowel disease in children.
    Wyllie R; Sarigol S
    Clin Pediatr (Phila); 1998 Jul; 37(7):421-5. PubMed ID: 9675435
    [No Abstract]   [Full Text] [Related]  

  • 45. [Salazosulfapyridine: old and new therapy concepts in inflammatory bowel diseases].
    Allgayer H; Kruis W
    Dtsch Med Wochenschr; 1985 Nov; 110(47):1827-9. PubMed ID: 2866083
    [No Abstract]   [Full Text] [Related]  

  • 46. Inflammatory bowel disease. Part II.
    Hansen R
    Proc Annu Meet Med Sect Am Counc Life Insur; 1978; ():41-9. PubMed ID: 39296
    [No Abstract]   [Full Text] [Related]  

  • 47. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

  • 49. Drug therapy: Sulfasalazine.
    Goldman P; Peppercorn MA
    N Engl J Med; 1975 Jul; 293(1):20-3. PubMed ID: 236516
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacotherapy of inflammatory bowel disease.
    Gardner RC
    J Maine Med Assoc; 1976 Jul; 67(7):206-14. PubMed ID: 9461
    [No Abstract]   [Full Text] [Related]  

  • 51. Mea culpa.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2008 Aug; 5(8):409. PubMed ID: 18670441
    [No Abstract]   [Full Text] [Related]  

  • 52. Proceedings: Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.
    Lendrum R; Walker JG; West B; Hill MJ
    Gut; 1974 Apr; 15(4):344. PubMed ID: 4151868
    [No Abstract]   [Full Text] [Related]  

  • 53. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.
    Korelitz BI; Present DH; Rubin PH; Fochios SE
    J Clin Gastroenterol; 1984 Feb; 6(1):27-31. PubMed ID: 6142067
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pancreatitis and pancreatic necrosis during sulfasalazine therapy.
    Faintuch J; Mott CB; Machado MC
    Int Surg; 1985; 70(3):271-2. PubMed ID: 2872181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sulfasalazine and new analogues in inflammatory bowel disease, with focus on Crohn's disease.
    van Hees PA
    Acta Gastroenterol Belg; 1987; 50(5):555-9. PubMed ID: 2902723
    [No Abstract]   [Full Text] [Related]  

  • 56. Therapy of inflammatory bowel disease, including use of immunosuppressive agents.
    Korelitz BI
    Clin Gastroenterol; 1980 May; 9(2):331-49. PubMed ID: 6104550
    [No Abstract]   [Full Text] [Related]  

  • 57. [New developments and trends in the drug therapy of chronic inflammatory bowel diseases].
    Ewe K
    Verh Dtsch Ges Inn Med; 1988; 94():178-84. PubMed ID: 2905098
    [No Abstract]   [Full Text] [Related]  

  • 58. Determination of salicylazosulphapyridine and sulphapyridine in plasma using high-performance liquid chromatography.
    Lanbeck K; Lindström B
    J Chromatogr; 1978 Jul; 154(2):321-4. PubMed ID: 28333
    [No Abstract]   [Full Text] [Related]  

  • 59. [Recurrence-preventive (remission preserving) therapy of chronic inflammatory bowel diseases].
    Kruis W; Pohl C
    Dtsch Med Wochenschr; 1998 Jan; 123(4):85-7. PubMed ID: 9487288
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunomodulation treatment of inflammatory bowel disease].
    Stave R
    Tidsskr Nor Laegeforen; 1984 Jan; 104(3):153-4. PubMed ID: 6142543
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.